Positron Corp. (OTCMKTS:POSC) Short Interest Up 683.3% in July

Key Points

• Positron Corp. experienced a significant increase in short interest in July, rising by 683.3% to 9,400 shares.
• The company's stock value decreased by 0.6% to $1.78, with trading volume at 2,400 shares compared to an average of 21,179 shares.
• Positron reported a quarterly revenue of $0.12 million and an EPS of ($0.05) during its last earnings report on May 15th.

Positron Corp. (OTCMKTS:POSC - Get Free Report) was the target of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 9,400 shares, agrowthof683.3% from the July 15th total of 1,200 shares. Based on an average trading volume of 86,200 shares, the days-to-cover ratio is presently 0.1 days. Currently,0.0% of the shares of the company are sold short. Currently,0.0% of the shares of the company are sold short. Based on an average trading volume of 86,200 shares, the days-to-cover ratio is presently 0.1 days.

Positron Stock Performance

POSC stock traded up $0.03 during midday trading on Friday, reaching $1.82. 28,388 shares of the company's stock traded hands, compared to its average volume of 30,526. The company has a 50-day moving average price of $1.60 and a two-hundred day moving average price of $1.66. Positron has a 52 week low of $0.92 and a 52 week high of $2.94. The firm has a market capitalization of $57.17 million, a PE ratio of -15.17 and a beta of 0.43.

Positron (OTCMKTS:POSC - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.05) earnings per share (EPS) for the quarter. The business had revenue of $0.12 million for the quarter.

Positron Company Profile

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines.